CDK13 drives clear cell renal carcinoma through METTL16-mediated m6A modification of ACLY mRNA - PubMed
8 days ago
- #CDK13
- #lipid metabolism
- #ccRCC
- CDK13 is identified as a key regulator in clear cell renal cell carcinoma (ccRCC), driving lipid dysregulation.
- CDK13 overexpression is linked to advanced tumor stages, poor prognosis, and abnormal lipid accumulation in ccRCC patients.
- Mechanistically, CDK13 phosphorylates METTL16, enhancing its activity to add m6A modifications to ACLY mRNA, which stabilizes the mRNA and increases acetyl-CoA production.
- The CDK13-METTL16-ACLY axis promotes lipogenesis and ccRCC aggressiveness, with disruption of this axis suppressing tumor growth and metastasis.
- Targeting CDK13 with the inhibitor 1NM-PP1 enhances the anticancer effects of METTL16 depletion, suggesting a potential therapeutic strategy for ccRCC.